Lon S Schneider
Overview
Explore the profile of Lon S Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
19292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang G, Li Y, McDade E, Xiong C, Hartz S, Bateman R, et al.
medRxiv
. 2025 Mar;
PMID: 40034778
Introduction: CDR-SB is a reliable and clinically meaningful composite for assessing treatment effects in Alzheimer's disease (AD) clinical trials. Small CDR-SB differences at the end of a trial often lead...
2.
Livingston G, Costafreda S, Kivimaki M, Mukadam N, Schneider L, Selbaek G, et al.
Lancet
. 2025 Feb;
405(10479):625-626.
PMID: 39986746
No abstract available.
3.
Livingston G, Costafreda S, Kivimaki M, Mukadam N, Selbaek G, Shirai K, et al.
Lancet
. 2025 Feb;
405(10479):623.
PMID: 39986742
No abstract available.
4.
Davis M, Robinson E, Koronyo Y, Salobrar-Garcia E, Rentsendorj A, Gaire B, et al.
Acta Neuropathol Commun
. 2025 Feb;
13(1):31.
PMID: 39955563
Pathological tau isoforms, including hyperphosphorylated tau at serine 396 (pS396-tau) and tau oligomers (Oligo-tau), are elevated in the retinas of patients with mild cognitive impairment (MCI) due to Alzheimer's disease...
5.
Wang L, Hu W, Dong F, Sheng C, Wu J, Han Y, et al.
Geroscience
. 2025 Jan;
PMID: 39888585
Brain network dynamics have been extensively explored in patients with subjective cognitive decline (SCD). However, these studies are susceptible to individual differences, scanning parameters, and other confounding factors. Therefore, how...
6.
Davis M, Robinson E, Koronyo Y, Salobrar-Garcia E, Rentsendorj A, Gaire B, et al.
bioRxiv
. 2024 Sep;
PMID: 39345568
Accumulation of pathological tau isoforms, especially hyperphosphorylated tau at serine 396 (pS396-tau) and tau oligomers, has been demonstrated in the retinas of patients with mild cognitive impairment (MCI) and Alzheimer's...
7.
Okonkwo O, Rivera Mindt M, Ashford M, Conti C, Strong J, Raman R, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2427073.
PMID: 39120898
Importance: Black or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionally affected by Alzheimer disease, but most research studies do not enroll adequate numbers of...
8.
Livingston G, Huntley J, Liu K, Costafreda S, Selbaek G, Alladi S, et al.
Lancet
. 2024 Aug;
404(10452):572-628.
PMID: 39096926
No abstract available.
9.
Zhu C, Schneider L, Elder G, Soleimani L, Grossman H, Aloysi A, et al.
Am J Geriatr Psychiatry
. 2024 Jul;
32(12):1402-1416.
PMID: 39013750
Objective: Understanding the course of individual neuropsychiatric symptoms (NPS) and their relationship with function is important for planning targeted interventions for preventing and delaying functional decline. This study aims to...
10.
Shi H, Mirzaei N, Koronyo Y, Davis M, Robinson E, Braun G, et al.
Acta Neuropathol
. 2024 Jul;
148(1):3.
PMID: 38980423
This study investigates various pathological tau isoforms in the retina of individuals with early and advanced Alzheimer's disease (AD), exploring their connection with disease status. Retinal cross-sections from predefined superior-temporal...